Neurological Institute Outcomes

373 obstructive sleep apnea (OSA) patients treated with positive airway pressure (PAP) had at least 2 visits from 2021–2022 with ESS data available for analysis. Among those patients whose baseline ESS score ≥ 10 (N = 128), 40.6% (N = 52) improved, 47.7% (N = 61) remained stable, and 11.7% (N = 15) worsened. Median duration of follow-up was 154 days (range, 1-639 days). Clinically meaningful change was defined as a total score change of 3, based on one-half the standard deviation.¹

530 OSA patients treated with PAP had at least 2 visits from 2021–2022 with PHQ-9 data available for analysis. Among those patients whose baseline PHQ-9 score ≥ 10 (N = 150), 33.3% (N = 50) improved, 56.0% (N = 84) remained stable, and 10.7% (N = 16) worsened. Median duration of follow-up was 208 days (range, 1-676 days). Clinically meaningful change was defined as a total score change of 5.²

685 OSA patients treated with PAP had at least 2 visits from 2021–2022 with PROMIS Mental Health data available for analysis. Among those patients whose baseline PROMIS Mental Health score ≤ 45 (N = 332), 27.4% (N = 91) improved, 64.8% (N = 215) remained stable, and 7.8% (N = 216) worsened. Median duration of follow-up was 256 days (range, 1-700 days). Clinically meaningful change was defined as a 5-unit change in T-score, based on one-half the standard deviation.¹

691 OSA patients treated with PAP had at least 2 visits from 2021–2022 with PROMIS Physical Health data available for analysis. Among those patients whose baseline PROMIS Physical Health score ≤ 45 (N = 394), 30.2% (N = 119) improved, 58.9% (N = 232) remained stable, and 10.9% (N = 43) worsened. Median duration of follow-up was 246 days (range, 1-714 days). Clinically meaningful change was defined as a 5-unit change in T-score, based on one-half the standard deviation.¹

427 OSA patients treated with PAP had at least 2 visits from 2021–2022 with PROMIS Sleep Disturbance data available for analysis. Among those patients whose baseline PROMIS Sleep Disturbance score ≥ 55 (N = 189), 49.7% (N = 94) improved, 39.2% (N = 74) remained stable, and 11.1% (N = 21) worsened. Median duration of follow-up was 168 days (range, 1-662 days). Clinically meaningful change was defined as a 5-unit change in T-score, based on one-half the standard deviation.¹

214 OSA patients treated with PAP had at least 2 visits from 2021–2022 with Sleep Time data available for analysis. Among those patients whose baseline Sleep Time ≤ 24 hours , 30.8% (N = 66) improved, 35% (N = 75) remained stable, and 34.1% (N = 73) worsened. Median duration of follow-up was 273 days (range, 2-701 days). Clinically meaningful change was defined as a 1-hour change, based on one-half the standard deviation.¹

37 OSA patients treated with HNS had at least 2 visits from 2021–2022 with ESS data available for analysis. Among those patients whose baseline ESS score ≥ 10 (N = 16), 37.5% (N = 6) improved, 37.5% (N = 6) remained stable, and 25% (N = 4) worsened. Median duration of follow-up was 150 days (range, 34-556 days). Clinically meaningful change was defined as a total score change of 3, based on one-half the standard deviation.¹

43 OSA patients treated with HNS had at least 2 visits from 2021–2022 with PHQ-9 data available for analysis. Among those patients whose baseline PHQ-9 score ≥ 10 (N = 10), 20% (N = 2) improved, 60% (N = 6) remained stable, and 20% (N = 2) worsened. Median duration of follow-up was 145 days (range, 56-478 days). Clinically meaningful change was defined as a total score change of 5.²

40 OSA patients treated with HNS had at least 2 visits from 2021–2022 with PROMIS Mental Health data available for analysis. Among those patients whose baseline PROMIS Mental Health score ≤ 45 (N = 10), 10% (N = 1) improved, 90% (N = 9) remained stable, and 0% (N = 0) worsened. Median duration of follow-up was 227 days (range, 76-677 days). Clinically meaningful change was defined as a 5-unit change in T-score, based on one-half the standard deviation.¹

41 OSA patients treated with HNS had at least 2 visits from 2021–2022 with PROMIS Physical Health data available for analysis. Among those patients whose baseline PROMIS Physical Health score ≤ 45 (N = 19), 26.3% (N = 5) improved, 47.4% (N = 9) remained stable, and 26.3% (N = 5) worsened. Median duration of follow-up was 230 days (range, 30-640 days). Clinically meaningful change was defined as a 5-unit change in T-score, based on one-half the standard deviation.¹

42 OSA patients treated with HNS had at least 2 visits from 2021–2022 with PROMIS Sleep Disturbance data available for analysis. Among those patients whose baseline PROMIS Sleep Disturbance score ≥ 55 (N = 18), 44.4% (N = 8) improved, 38.9% (N = 7) remained stable, and 16.7% (N = 3) worsened. Median duration of follow-up was 187 days (range, 28-556 days). Clinically meaningful change was defined as a 5-unit change in T-score, based on one-half the standard deviation.¹

19 OSA patients treated with HNS had at least 2 visits from 2021–2022 with Sleep Time data available for analysis. Among those patients whose baseline Sleep Time ≤ 24 hours (N = 19), 26.3% (N = 5) improved, 57.9% (N = 11) remained stable, and 15.8% (N = 3) worsened. Median duration of follow-up was 308 days (range, 189-556 days). Clinically meaningful change was defined as a 1-hour change, based on one-half the standard deviation.¹